1. What Is the Hereditary Cancer Testing Market?
The Hereditary Cancer Testing Market covers germline genetic testing identifying inherited mutations in BRCA1/2, Lynch syndrome mismatch repair genes, TP53, PALB2, ATM, and multigene panel testing for cancer risk assessment. Hereditary cancer testing encompasses single-gene BRCA testing, multigene panel testing, cascade family testing, and population-level cancer risk screening. Market dynamics reflect PARP inhibitor prescribing requiring BRCA testing, hereditary cancer programme expansion beyond high-risk families to population testing, and mainstreaming genetic testing through primary care.
2. Hereditary Cancer Testing Market Size & Forecast
3. Emerging Technologies
- Rapid germline genetic testing turnaround from 14 days to 7 days enabling treatment-concurrent BRCA testing are advancing as clinical workflow tools. Growing adoption at oncology practices is driven by PARP inhibitor prescribing decision timing requirements.
- Multigene panel variant of uncertain significance reclassification programmes improving clinical utility of ambiguous results are advancing as interpretation tools. Growing adoption at hereditary cancer laboratories is driven by VUS management and reclassification requirements.
- AI-driven hereditary cancer risk models integrating genetic, family history, and epidemiological data are advancing as counselling tools. Growing adoption at genetic counsellors is driven by pre-test and post-test counselling efficiency requirements.
- Cascade family testing programmes systematically notifying and testing relatives of newly identified hereditary cancer mutation carriers are advancing. Growing adoption is driven by family risk management and prevention programme requirements.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Companion Diagnostic Market.
4. Key Market Opportunity
The largest addressable opportunity within the Hereditary Cancer Testing Market is the oncology PARP inhibitor-driven BRCA testing sub-market, where olaparib, rucaparib, and niraparib prescribing label BRCA requirements create structured oncology testing demand. Population hereditary cancer screening creates a large long-term volume expansion opportunity as NHS and commercial programmes extend beyond family-history-selected populations. Multigene panel testing creates a premium laboratory service opportunity as comprehensive panels replace single-gene testing across hereditary cancer syndromes. Asia Pacific hereditary cancer testing creates geographic expansion as Japanese, Chinese, and South Korean hereditary cancer programme investment grows.
5. Top Companies in the Hereditary Cancer Testing Market
The following organisations hold leading positions in the Hereditary Cancer Testing Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Myriad Genetics
- Invitae
- Ambry Genetics
- GeneDx
- Blueprint Genetics
- Color Genomics
- Guardant Health
- Foundation Medicine
- Laboratory Corporation
- Quest Diagnostics
6. Market Segmentation
The Hereditary Cancer Testing Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Test Type | Single-Gene BRCAMultigene Panel 30-plus GenesLynch Syndrome MMRPopulation Screening |
| By Indication | Hereditary Breast OvarianLynch SyndromeLi-FraumeniHereditary PancreaticProstate Cancer |
| By Setting | Specialist GeneticsOncologyPrimary CareDirect-to-Consumer |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Hereditary Cancer Testing Market trajectory over the forecast period:
Myriad Genetics BRACAnalysis Achieves 5 Million Cumulative BRCA Tests Supporting PARP Inhibitor Prescribing.Myriad Genetics reporting 5 million cumulative BRCA tests through 2024 and 40 percent BRCA testing rate among new BRCA-relevant cancer diagnoses demonstrates hereditary cancer testing commercial scale. BRCA testing integration into oncology PARP inhibitor prescribing for ovarian, breast, and prostate cancer driving oncology-initiated testing demonstrates the therapeutic prescribing driver for hereditary cancer testing.
Invitae 84-Gene Hereditary Cancer Panel Achieves 1 Million Annual Hereditary Cancer Tests.Invitae reaching 1 million annual hereditary cancer multigene panel tests in 2024 with 84-gene panel covering 30-plus hereditary cancer syndromes demonstrates multi-syndrome hereditary cancer panel at commercial scale. Invitae achieving USD 50 hereditary cancer panel pricing through volume demonstrates multigene panel cost reduction enabling broader testing access beyond specialist genetics.
Population Hereditary Cancer Screening Programmes Expand Beyond High-Risk Family History Indication.Myriad proactive hereditary cancer population screening pilots and UK Genomics England NHS programme testing 100,000 primary care patients for BRCA and Lynch syndrome in 2024 demonstrate hereditary cancer testing mainstreaming. Population BRCA screening in unselected women achieving 10-fold higher carrier detection than family-history-based testing demonstrates population screening superiority.
For related market intelligence, see the Car T Cell Therapy Market.
8. Segmental Analysis
By test type, the Multigene Panel Testing segment dominated the Hereditary Cancer Testing Market in 2025. Representing the largest revenue category as comprehensive 30-plus gene panels replace single-gene BRCA testing. The Population Cancer Screening segment is the fastest-growing category, advancing as primary care and direct-to-consumer programmes expand hereditary cancer detection beyond specialist genetics.
By indication, the Hereditary Breast Ovarian Cancer BRCA segment dominated the Hereditary Cancer Testing Market in 2025. Representing the largest indication revenue share. The Lynch Syndrome Colorectal segment is the fastest-growing indication category, advancing as clinical protocol standardisation and reimbursement expansion broaden market access. The Hereditary Breast Ovarian Cancer BRCA structural position and Lynch Syndrome Colorectal growth momentum establish the core indication segmentation dynamic for the Hereditary Cancer Testing Market through 2034.
By setting, the Specialist Genetics segment dominated the Hereditary Cancer Testing Market in 2025, as clinical genetics programmes at cancer centres generating BRCA1/2, Lynch syndrome, and multi-gene panel testing represent the primary revenue base. Primary Care setting is the fastest-growing category, driven by mainstreaming of cascade testing and population-based hereditary cancer screening through primary care physician ordering.
9. Regional Analysis
Regional demand patterns across the Hereditary Cancer Testing Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Hereditary Cancer Testing Market in 2025, holding 53.4% of the global market. Clinical genetics laboratories, hereditary cancer assessment clinics, and health insurers are deploying hereditary cancer testing to identify BRCA, Lynch syndrome, and other pathogenic variant carriers for risk-stratified cancer prevention programmes. FDA companion diagnostic approvals for BRCA-targeting therapies and USPSTF hereditary cancer screening recommendations are encouraging healthcare providers and payers to cover hereditary cancer genetic testing. High genetic testing laboratory capacity, established clinical genetics infrastructure, and growing oncology companion diagnostic adoption are generating strong regional hereditary cancer testing demand.
Highest CAGR Region
Europe is expected to register the highest CAGR of 18.89% during the forecast period. Clinical genetics organisations, oncology centres, and genetic testing laboratories across Germany, France, the United Kingdom, and the Netherlands are expanding hereditary cancer testing programmes to identify at-risk populations and guide preventive management. European Medicines Agency companion diagnostic requirements and growing clinical genetics research infrastructure are encouraging hereditary cancer testing adoption across oncology and primary care settings. Rising awareness of hereditary cancer risk among European populations and increasing clinical guideline recommendations for genetic risk assessment are generating demand.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Hereditary Cancer Testing Market was valued at USD 5.44 Bn in 2025 and is projected to reach USD 18.71 Bn by 2034, growing at a CAGR of 14.7% over the 2026–2034 forecast period.
The Hereditary Cancer Testing Market is projected to grow at a CAGR of 14.7% from 2026 to 2034.
North America accounted for the largest share of the Hereditary Cancer Testing Market in 2025, holding 53.4% of the global market.
The leading companies in the Hereditary Cancer Testing Market include Myriad Genetics, Invitae, Ambry Genetics, GeneDx, Blueprint Genetics, Color Genomics, Guardant Health, Foundation Medicine, Laboratory Corporation, Quest Diagnostics.
Myriad genetics bracanalysis achieves 5 million cumulative brca tests supporting parp inhibitor prescribing.
By test type, the Multigene Panel Testing segment dominated the Hereditary Cancer Testing Market in 2025.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.